Details for Patent: 10,174,073

Which drugs does patent 10,174,073 protect, and when does it expire?

Patent 10,174,073 protects OCALIVA and is included in one NDA.

This patent has seventy-three patent family members in twenty-four countries.

Summary for Patent: 10,174,073

Title:	Preparation and uses of obeticholic acid
Abstract:	The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
Inventor(s):	André Steiner, Heidi Waenerlund Poulsen, Emilie Jolibois, Melissa Rewolinski, Ralf Gross, Emma Sharp, Fiona Dubas-Fisher, Alex Eberlin
Assignee:	Sigma Aldrich Co Ltd , Intercept Pharmaceuticals Inc
Application Number:	US15/496,398
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,174,073
Patent Claim Types: see list of patent claims	Composition; Process;

Drugs Protected by US Patent 10,174,073

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Intercept	OCALIVA	obeticholic acid	TABLET;ORAL	207999-001	May 27, 2016		DISCN	Yes	No				Y
Intercept	OCALIVA	obeticholic acid	TABLET;ORAL	207999-002	May 27, 2016		DISCN	Yes	No				Y

International Family Members for US Patent 10,174,073

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013277429
Australia	2016200832
Australia	2016375566
Australia	2017204057
Australia	2018241172